Switching to Faricimab Improves Diabetic Macular Edema Symptoms

Strategic Insights -

A new systematic review and meta-analysis published in the Graefe's Archive for Clinical and Experimental Ophthalmology has found that switching to faricimab after prior anti-vascular endothelial growth factor (VEGF) therapy can significantly improve symptoms of diabetic macular edema (DME). The study, conducted by researchers at Tabriz University of Medical Sciences, analyzed data from 15 studies published between 2022 and January 2025, involving a total of 564 patients.

Key Takeaways:

  • The study found that switching to faricimab resulted in significant improvement in best-corrected visual acuity (BCVA) and central macular thickness (CMT) compared to prior anti-VEGF therapy.
  • The pooled mean difference in BCVA was -0.03 at 1 month post-faricimab injection and -0.05 at 3-12 months post-injection.
  • CMT also showed significant improvement after switching to faricimab, with a pooled mean difference of -54.69 μm and -103.5 μm at 1 month and 3-12 months post-injection, respectively.
  • The study suggested that treatment intervals were significantly prolonged after switching to faricimab, with a mean difference of 1.53 weeks.
  • The researchers concluded that switching to faricimab can be a viable treatment option for patients with persistent DME.

Statistics:

  • 564 patients were included in the study.
  • 15 studies were analyzed.
  • 620 eyes were included in the systematic review.
  • The mean difference in BCVA was -0.03 at 1 month post-faricimab injection and -0.05 at 3-12 months post-injection.
  • The mean difference in CMT was -54.69μm and -103.5 μm at 1 month and 3-12 months post-injection, respectively.
  • The treatment intervals were significantly prolonged after switching to faricimab, with a mean difference of 1.53 weeks.

Sources:

  • "Switching To Faricimab After Prior Anti-vascular Endothelial Growth Factor Therapy for Persistent Diabetic Macular Edema: a Systematic Review and Meta-analysis" published in the Graefe's Archive for Clinical and Experimental Ophthalmology, 2025.
  • Authors: Narges Hassanpoor, Ali Tahmasebi, Nazanin Ebrahimiadib, Mohammadreza Niyousha, Tabriz University of Medical Sciences.
  • Springer - www.springer.com; Graefe's Archive for Clinical and Experimental Ophthalmology - www.springerlink.com/content/0721-832x/
  • NewsRx. Findings from Tabriz University of Medical Sciences in the Area of Macular Edema Described (Switching To Faricimab After Prior Anti-vascular Endothelial Growth Factor Therapy for Persistent Diabetic Macular Edema: a Systematic Review and ...). Immunotherapy Weekly. July 23, 2025; p 55.